{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Age-Related+Macular+Degeneration+%28ARMD%29",
    "query": {
      "condition": "Age-Related Macular Degeneration (ARMD)"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 908,
    "total_pages": 91,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Age-Related+Macular+Degeneration+%28ARMD%29&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-03T18:50:45.463Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05275205",
      "title": "Safety, Tolerability, and Efficacy Study of UBX1325 in Patients With Neovascular Age-Related Macular Degeneration (ENVISION)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neovascular Age-related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "UBX1325 injection 50 μL",
          "type": "DRUG"
        },
        {
          "name": "EYLEA® (aflibercept) Injection 2 mg (0.05mL)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Unity Biotechnology, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 51,
      "start_date": "2022-03-02",
      "completion_date": "2023-07-25",
      "has_results": true,
      "last_update_posted_date": "2024-08-07",
      "last_synced_at": "2026-10-03T18:50:45.463Z",
      "location_count": 14,
      "location_summary": "Beverly Hills, California • Huntington Beach, California • Longmont, Colorado + 11 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Longmont",
          "state": "Colorado"
        },
        {
          "city": "Deerfield Beach",
          "state": "Florida"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05275205"
    },
    {
      "nct_id": "NCT03364153",
      "title": "Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stargardt's Macular Dystrophy"
      ],
      "interventions": [
        {
          "name": "avacincaptad pegol",
          "type": "DRUG"
        },
        {
          "name": "Sham",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Global Development, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 121,
      "start_date": "2018-01-12",
      "completion_date": "2025-03-31",
      "has_results": true,
      "last_update_posted_date": "2026-04-15",
      "last_synced_at": "2026-10-03T18:50:45.463Z",
      "location_count": 17,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Gainesville, Florida + 14 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Pensacola",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03364153"
    },
    {
      "nct_id": "NCT00071227",
      "title": "Eye Injections of Triamcinolone Acetonide for Retinal Blood Vessel Disorders",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Macular Degeneration",
        "Retinal Vein Occlusion"
      ],
      "interventions": [
        {
          "name": "Triamcinolone Acetonide (TAC-PF)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Eye Institute (NEI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2003-10-15",
      "completion_date": "2007-08-15",
      "has_results": false,
      "last_update_posted_date": "2017-07-02",
      "last_synced_at": "2026-10-03T18:50:45.463Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00071227"
    },
    {
      "nct_id": "NCT02462486",
      "title": "Safety and Efficacy of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Abicipar Pegol",
          "type": "DRUG"
        },
        {
          "name": "Ranibizumab",
          "type": "DRUG"
        },
        {
          "name": "Sham Procedure",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 949,
      "start_date": "2015-06-25",
      "completion_date": "2019-06-06",
      "has_results": true,
      "last_update_posted_date": "2020-07-30",
      "last_synced_at": "2026-10-03T18:50:45.463Z",
      "location_count": 73,
      "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 65 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Springdale",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02462486"
    },
    {
      "nct_id": "NCT00943072",
      "title": "Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Macular Edema Secondary to Central Retinal Vein Occlusion"
      ],
      "interventions": [
        {
          "name": "VEGF Trap-Eye 2.0mg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sham",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 189,
      "start_date": "2009-07",
      "completion_date": "2012-04",
      "has_results": true,
      "last_update_posted_date": "2013-05-27",
      "last_synced_at": "2026-10-03T18:50:45.463Z",
      "location_count": 46,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 41 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Arcadia",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00943072"
    },
    {
      "nct_id": "NCT04640272",
      "title": "A Multi-Center, Open Label, Extension Study Assessing the Efficacy and Safety of Additional Intravitreal Injections of RBM-007 in Subjects With Wet Age-related Macular Degeneration",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Exudative Age-related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "RBM-007",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ribomic USA Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "55 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2020-11-03",
      "completion_date": "2021-12-22",
      "has_results": true,
      "last_update_posted_date": "2023-06-08",
      "last_synced_at": "2026-10-03T18:50:45.463Z",
      "location_count": 6,
      "location_summary": "Phoenix, Arizona • Sacramento, California • Walnut Creek, California + 3 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "McAllen",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04640272"
    },
    {
      "nct_id": "NCT03630952",
      "title": "Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-2)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Neovascular Age-related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "0.5 mg Conbercept Intravitreal Injection",
          "type": "BIOLOGICAL"
        },
        {
          "name": "1.0 mg Conbercept Intravitreal Injection",
          "type": "BIOLOGICAL"
        },
        {
          "name": "2.0 mg Aflibercept Intravitreal Injection",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Chengdu Kanghong Biotech Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 1157,
      "start_date": "2018-12-21",
      "completion_date": "2021-05-19",
      "has_results": false,
      "last_update_posted_date": "2021-06-23",
      "last_synced_at": "2026-10-03T18:50:45.463Z",
      "location_count": 69,
      "location_summary": "Phoenix, Arizona • Springdale, Arkansas • Arcadia, California + 61 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Springdale",
          "state": "Arkansas"
        },
        {
          "city": "Arcadia",
          "state": "California"
        },
        {
          "city": "Arcadia",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03630952"
    },
    {
      "nct_id": "NCT01670643",
      "title": "Reading Performance With a Video Magnifier",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Video camera magnifier",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Mary Lou Jackson",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "40 Years to 90 Years"
      },
      "enrollment_count": 120,
      "start_date": "2010-01",
      "completion_date": "2011-02",
      "has_results": false,
      "last_update_posted_date": "2017-03-27",
      "last_synced_at": "2026-10-03T18:50:45.463Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01670643"
    },
    {
      "nct_id": "NCT06006585",
      "title": "A Study to Test How Well Different Doses of BI 771716 Are Tolerated by People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Geographic Atrophy"
      ],
      "interventions": [
        {
          "name": "BI 771716",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2023-10-06",
      "completion_date": "2024-05-24",
      "has_results": false,
      "last_update_posted_date": "2025-02-18",
      "last_synced_at": "2026-10-03T18:50:45.463Z",
      "location_count": 9,
      "location_summary": "Walnut Creek, California • Jacksonville, Florida • Melbourne, Florida + 6 more",
      "locations": [
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Melbourne",
          "state": "Florida"
        },
        {
          "city": "Eugene",
          "state": "Oregon"
        },
        {
          "city": "Erie",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06006585"
    },
    {
      "nct_id": "NCT06510816",
      "title": "A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Geographic Atrophy"
      ],
      "interventions": [
        {
          "name": "Vonaprument",
          "type": "DRUG"
        },
        {
          "name": "Sham Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Annexon, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 659,
      "start_date": "2024-07-30",
      "completion_date": "2027-07-31",
      "has_results": false,
      "last_update_posted_date": "2026-05-04",
      "last_synced_at": "2026-10-03T18:50:45.463Z",
      "location_count": 71,
      "location_summary": "Scottsdale, Arizona • Beverly Hills, California • Fullerton, California + 64 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Modesto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06510816"
    }
  ]
}